Published in Neurology on December 13, 2005
Prevalence and factors associated with sleep disturbances among early-treated HIV-infected persons. Clin Infect Dis (2012) 1.06
Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology (2013) 0.95
HIV-related neuropathy: current perspectives. HIV AIDS (Auckl) (2013) 0.93
Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya. Am J Trop Med Hyg (2010) 0.91
The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. J Neurol Sci (2011) 0.90
Utility of quantitative sensory testing and screening tools in identifying HIV-associated peripheral neuropathy in Western Kenya: pilot testing. PLoS One (2010) 0.88
Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. HIV Med (2008) 0.87
HIV-associated sensory neuropathy in HIV-1 infected patients at the Douala General Hospital in Cameroon: a cross-sectional study. AIDS Res Ther (2012) 0.86
Sensory, psychological, and metabolic dysfunction in HIV-associated peripheral neuropathy: A cross-sectional deep profiling study. Pain (2014) 0.85
Measures of small-fiber neuropathy in HIV infection. Auton Neurosci (2012) 0.84
HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol (2014) 0.81
Distal sensory polyneuropathy is associated with neuropsychological test performance among persons with HIV. J Int Neuropsychol Soc (2012) 0.81
Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology (2010) 0.80
Microglial content-dependent inhibitory effects of calcitonin gene-related peptide (CGRP) on murine retroviral infection of glial cells. J Neuroimmunol (2015) 0.79
Screening for HIV-associated peripheral neuropathy in resource-limited settings. Muscle Nerve (2013) 0.78
Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy. Clin Infect Dis (2011) 0.78
Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics (2009) 0.78
Symptomatology of peripheral neuropathy in an African language. PLoS One (2013) 0.77
In Vivo Confocal Microscopy of the Human Cornea in the Assessment of Peripheral Neuropathy and Systemic Diseases. Biomed Res Int (2015) 0.77
Prevalence of peripheral neuropathy and its associated demographic and health status characteristics, among people on antiretroviral therapy in Rwanda. BMC Public Health (2014) 0.77
Sensory neuropathy and metabolic risk factors in human immune deficiency virus infected South Africans receiving protease inhibitors. AIDS Res Ther (2015) 0.76
Cognitive demands during quiet standing elicit truncal tremor in two frequency bands: differential relations to tissue integrity of corticospinal tracts and cortical targets. Front Hum Neurosci (2015) 0.75
HIV neuropathy: an in vivo confocal microscopic study. J Neurovirol (2012) 0.75
Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy. PLoS One (2015) 0.75
Role of TNF block genetic variants in HIV-associated sensory neuropathy in black Southern Africans. Eur J Hum Genet (2014) 0.75
Assessment of vibratory sensation with a tuning fork at different sites in Japanese patients with diabetes mellitus. J Diabetes Investig (2013) 0.75
Genetics of HIV-associated sensory neuropathy and related pain in Africans. J Neurovirol (2017) 0.75
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol (2009) 2.14
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain (2004) 1.90
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther (2012) 1.79
Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS (2002) 1.68
HIV-associated sensory neuropathies. AIDS (2002) 1.65
Evaluating sleep and cognition in HIV. J Acquir Immune Defic Syndr (2013) 1.64
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol (2011) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS (2010) 1.56
Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read (2002) 1.56
Peripheral neuropathy in HIV: prevalence and risk factors. AIDS (2011) 1.53
4: Acute community-acquired meningitis and encephalitis. Med J Aust (2002) 1.52
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
The widening gap between clinical, teaching and research work. Med J Aust (2009) 1.46
Diagnostic utility of the subjective peripheral neuropathy screen in HIV-infected persons with peripheral sensory polyneuropathy. AIDS Read (2005) 1.46
Low atazanavir concentrations in cerebrospinal fluid. AIDS (2009) 1.45
Academic health science centres in Australia: let's get competitive. Med J Aust (2011) 1.43
Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Acad Radiol (2002) 1.43
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology (2007) 1.41
Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol (2008) 1.40
Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol (2003) 1.39
Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues. J Neurovirol (2006) 1.33
Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. J Acquir Immune Defic Syndr (2005) 1.32
Astrocyte specific viral strains in HIV dementia. Ann Neurol (2004) 1.26
Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol (2005) 1.23
HIV-associated opportunistic infections of the CNS. Lancet Neurol (2012) 1.22
Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain (2007) 1.21
Sleep, function and HIV: a multi-method assessment. AIDS Behav (2013) 1.20
Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol (2006) 1.19
Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology (2007) 1.17
Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol (2007) 1.15
Saving the clinician-scientist: report of the ANA long range planning committee. Ann Neurol (2006) 1.12
Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol (2011) 1.12
Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol (2006) 1.11
Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol (2002) 1.11
Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol (2003) 1.11
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol (2009) 1.09
Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr (2002) 1.09
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol (2008) 1.08
Epidermal reinnervation after intracutaneous axotomy in man. J Comp Neurol (2003) 1.08
Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr (2006) 1.08
Depressive symptoms, quality of life, and neuropsychological performance in HIV/AIDS: the impact of gender and injection drug use. J Neurovirol (2005) 1.08
Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology (2005) 1.07
Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol (2007) 1.06
Increased vulnerability of ApoE4 neurons to HIV proteins and opiates: protection by diosgenin and L-deprenyl. Neurobiol Dis (2006) 1.06
Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy. Brain (2011) 1.05
Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol (2005) 1.04
Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic. J Neurol Sci (2011) 1.02
HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs (2012) 1.01
Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol (2006) 1.01
Relationship of depression and catastrophizing to pain, disability, and medication adherence in patients with HIV-associated sensory neuropathy. AIDS Care (2011) 1.01
Recent developments in the HIV neuropathies. Curr Opin Neurol (2003) 1.00
Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia. J Infect Dis (2004) 1.00
Novel pathway of human immunodeficiency virus type 1 uptake and release in astrocytes. Virology (2006) 0.99
Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol (2012) 0.99
Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr (2005) 0.99
Progression of HIV-associated dementia treated with HAART. AIDS Read (2002) 0.98
Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol (2006) 0.98
Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol (2005) 0.98
CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J (2009) 0.97
A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One (2007) 0.97
Macrophage-mediated dorsal root ganglion damage precedes altered nerve conduction in SIV-infected macaques. Am J Pathol (2011) 0.97
Predictors of outcome in acute encephalitis. Neurology (2013) 0.97
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. J Clin Virol (2003) 0.96
Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve (2006) 0.96
Seroepidemiology of Klebsiella pneumoniae in an Australian Tertiary Hospital and its implications for vaccine development. J Clin Microbiol (2006) 0.95
Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr (2012) 0.95
Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons. J Acquir Immune Defic Syndr (2013) 0.95
Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long-term survivors infected from a single source. Virol J (2007) 0.95
FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol (2003) 0.95
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS (2009) 0.95
CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates. J Neurovirol (2010) 0.94
Replication-dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo. J Acquir Immune Defic Syndr (2007) 0.94
Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. J Neurovirol (2010) 0.94
Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr (2013) 0.93